3D Medicines Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	445.65	634.95	567.39	60.26	-
Revenue Growth (YoY)	-29.81%	11.91%	841.57%	-	-
Cost of Revenue	73.91	110.94	102.18	11.43	-
Gross Profit	371.74	524.01	465.21	48.83	-
Selling, General & Admin	314.19	595.89	500.49	193.79	40.53
Research & Development	180.72	425.5	350.86	371.16	263.97
Other Operating Expenses	-	-	-	4.28	-
Operating Expenses	495.17	1,021	851.38	569.36	304.5
Operating Income	-123.43	-497.25	-386.17	-520.53	-304.5
Interest Expense	-9.5	-7.77	-3.11	-1.53	-8.06
Interest & Investment Income	25.76	19.47	9.12	5.93	1.77
Currency Exchange Gain (Loss)	8.98	-2.55	34.86	-3.7	-5.93
Other Non Operating Income (Expenses)	-99.88	-82.45	-705.74	-941.21	-318.66
EBT Excluding Unusual Items	-198.08	-570.56	-1,051	-1,461	-635.38
Gain (Loss) on Sale of Investments	-0.89	8.09	-0.99	0.18	-
Gain (Loss) on Sale of Assets	-	-	-	-0.96	-0
Asset Writedown	-4.07	-	-	-	-
Other Unusual Items	3.66	-	-	-	-
Pretax Income	-199.38	-562.47	-1,052	-1,462	-635.38
Income Tax Expense	-	0.06	-	-	-
Earnings From Continuing Operations	-199.38	-562.52	-1,052	-1,462	-635.38
Minority Interest in Earnings	16.72	37.82	27.68	27.73	-
Net Income	-182.66	-524.7	-1,024	-1,434	-635.38
Net Income to Common	-182.66	-524.7	-1,024	-1,434	-635.38
Shares Outstanding (Basic)	245	228	45	39	46
Shares Outstanding (Diluted)	245	228	45	39	46
Shares Change (YoY)	7.22%	402.26%	16.48%	-14.36%	-
EPS (Basic)	-0.75	-2.30	-22.52	-36.72	-13.93
EPS (Diluted)	-0.75	-2.30	-22.52	-36.72	-13.93
Free Cash Flow	-255.94	-150.74	-332.76	-420.95	-289.48
Free Cash Flow Per Share	-1.04	-0.66	-7.32	-10.78	-6.35
Gross Margin	83.41%	82.53%	81.99%	81.03%	-
Operating Margin	-27.70%	-78.31%	-68.06%	-863.81%	-
Profit Margin	-40.99%	-82.64%	-180.54%	-2379.84%	-
Free Cash Flow Margin	-57.43%	-23.74%	-58.65%	-698.56%	-
EBITDA	-114.53	-489.39	-378.3	-516.78	-303.35
EBITDA Margin	-25.70%	-77.08%	-66.67%	-	-
D&A For EBITDA	8.91	7.86	7.87	3.75	1.15
EBIT	-123.43	-497.25	-386.17	-520.53	-304.5
EBIT Margin	-27.70%	-78.31%	-68.06%	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.